Airain ltd lessened its stake in shares of Mylan N.V. (NASDAQ:MYL) by 67.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,932 shares of the company’s stock after selling 67,253 shares during the quarter. Airain ltd’s holdings in Mylan N.V. were worth $1,240,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in MYL. andra ap fonden acquired a new stake in shares of Mylan N.V. during the second quarter valued at $939,000. prudential financial inc. boosted its stake in shares of Mylan N.V. by 165.9% during the second quarter. Prudential Financial Inc. now owns 1,640,316 shares of the company’s stock valued at $63,677,000 after acquiring an additional 1,023,376 shares during the last quarter. great lakes advisors llc boosted its stake in shares of Mylan N.V. by 112.1% during the second quarter. Great Lakes Advisors LLC now owns 31,202 shares of the company’s stock valued at $1,211,000 after acquiring an additional 16,488 shares during the last quarter. usca ria llc boosted its stake in shares of Mylan N.V. by 33.3% during the second quarter. Usca Ria LLC now owns 19,325 shares of the company’s stock valued at $750,000 after acquiring an additional 4,825 shares during the last quarter. Finally, Cutter & co brokerage inc. boosted its stake in shares of Mylan N.V. by 26.8% during the second quarter. Cutter & CO Brokerage Inc. now owns 22,930 shares of the company’s stock valued at $890,000 after acquiring an additional 4,850 shares during the last quarter. Hedge funds and other institutional investors own 71.97% of the company’s stock.
A number of brokerages have issued reports on MYL. Cantor Fitzgerald restated a “hold” rating and issued a $34.00 price objective on shares of Mylan N.V. in a report on Friday, September 8th. BidaskClub upgraded Mylan N.V. from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th. ValuEngine downgraded Mylan N.V. from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Argus downgraded Mylan N.V. from a “buy” rating to a “hold” rating and cut their price objective for the stock from $47.59 to $29.39 in a report on Tuesday, August 22nd. Finally, Mizuho restated a “buy” rating and issued a $37.00 price objective (down from $53.00) on shares of Mylan N.V. in a report on Sunday, August 20th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Mylan N.V. has a consensus rating of “Hold” and an average price target of $43.43.
WARNING: “Mylan N.V. (NASDAQ:MYL) Position Cut by Airain ltd” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/09/17/mylan-n-v-myl-stake-lowered-by-airain-ltd.html.
Shares of Mylan N.V. (NASDAQ:MYL) traded down 2.56% on Friday, hitting $32.03. The stock had a trading volume of 20,184,738 shares. Mylan N.V. has a 1-year low of $29.39 and a 1-year high of $45.87. The firm’s 50-day moving average is $32.33 and its 200 day moving average is $37.58. The stock has a market cap of $17.18 billion, a P/E ratio of 25.89 and a beta of 1.31.
Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The business had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3 billion. During the same quarter in the previous year, the firm posted $1.16 earnings per share. The firm’s quarterly revenue was up 15.7% on a year-over-year basis. equities analysts forecast that Mylan N.V. will post $4.52 EPS for the current year.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mylan N.V. and related companies with MarketBeat.com’s FREE daily email newsletter.